Edition:
United States

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

6,485JPY
5 Dec 2016
Change (% chg)

¥-99 (-1.50%)
Prev Close
¥6,584
Open
¥6,545
Day's High
¥6,598
Day's Low
¥6,475
Volume
848,200
Avg. Vol
987,075
52-wk High
¥8,486
52-wk Low
¥5,366

Select another date:

Thu, Nov 17 2016

BRIEF-Eisai Co says FDA grants fast track designation for development of E2609

* Eisai inc - first phase 3 study for e2609 in clinical trial program will enroll 1,330 patients with biomarkers confirmed for early alzheimer's disease

Eisai latest cancer drugmaker to win UK approval after price cut

LONDON Cancer drugmakers are cutting prices to ensure their medicines are used routinely on Britain's National Health Service, following the overhaul of a cancer drug funding scheme, with Japan's Eisai the latest to win approval.

Eisai latest cancer drugmaker to win UK approval after price cut

LONDON, Nov 3 Cancer drugmakers are cutting prices to ensure their medicines are used routinely on Britain's National Health Service, following the overhaul of a cancer drug funding scheme, with Japan's Eisai the latest to win approval.

BRIEF-Halozyme Therapeutics says Eisai and Halozyme initiate Phase 1b/2 clinical trial

* Eisai and Halozyme initiate Phase 1b/2 clinical trial with first patient dosing of eribulin in combination with PEGPH20 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

BRIEF-Eisai, Arena announce regulatory approval of VENESPRI in Mexico

* Eisai and Arena Pharmaceuticals announce regulatory approval of VENESPRI (lorcaserin HCl) in Mexico

BRIEF-R&I affirms Eisai's rating at "A+" and stable outlook

* Says rating and Investment Information, Inc. (R&I) affirmed the rating on Eisai at "A+"

Select another date: